Because naturally occurring cancers in dogs often mimic human disease, Immuvera uses comparative oncology to accelerate the development of both veterinary and human treatments. This mission demands a multidisciplinary team that spans science, clinical development, manufacturing and regulation.

Welcoming Gry Stensrud as Chief Technical Officer

To expand its technical expertise, Immuvera has appointed Dr. Gry Stensrud as Chief Technical Officer. Dr. Stensrud holds a Ph.D. in pharmaceutical technology and brings more than 25 years of experience across biotechnology, pharmaceutical and medical technology sector. She has held senior roles at GE Healthcare, Photocure and Lytix Biopharma, where she oversaw chemistry, manufacturing and controls (CMC), quality and pharmaceutical development from preclinical research through to commercial scale. Her broad technical background will help Immuvera develop scalable, high quality immunotherapies and navigate the complexities of process development and manufacturing.

Bringing regulatory depth: Anja E. H. Holm joins as Head of Regulatory Affairs

Regulatory expertise is critical for transforming laboratory breakthroughs into approved therapies. Anja E. H. Holm, a trained veterinarian from the University of Copenhagen, joins Immuvera as Head of Regulatory Affairs. Dr. Holm has nearly 25 years of experience in veterinary regulatory affairs. She previously spent twelve years on the Committee for Veterinary Medicinal Products (CVMP) at the European Medicines Agency, including serving as Chair. Her deep knowledge of regulatory frameworks and her international perspective will be essential as Immuvera prepares its therapies for clinical trials and seeks approvals in multiple jurisdictions.

CEO of Immuvera Therapeutics, Jørund Sollid

“Immuvera believes that studying and treating naturally developing cancers in dogs can advance human cancer research. The company’s therapies are moving toward randomized clinical trials in dogs, the addition of Stensrud and Holm strengthens the cross-functional expertise needed to reach this milestone. Together, they reinforce the company’s position in biotechnology and veterinary health and complement its existing team of scientists, clinicians and business developers.”

We warmly welcome Gry Stensrud and Dr. Anja E. H. Holm to the Immuvera family and look forward to their contributions as we work to bring innovative cancer treatments from the veterinary clinic to the wider world.